Novel point mutation in exon 10 of theRET proto-oncogene in a family with medullary thyroid carcinoma

This publication has 17 references indexed in Scilit:

• Germline Dinucleotide Mutation in Codon 883 of theRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 Mutation
  Journal of Clinical Endocrinology & Metabolism, 1997
• Update on the profile of multiple endocrine neoplasia type 2aRET mutations
  Cancer, 1997
• Mutation of RET codon 768 is associated with the FMTC phenotype
  Clinical Genetics, 1997
• The Relationship Between Specific RET Proto-oncogene Mutations and Disease Phenotype in Multiple Endocrine Neoplasia Type 2
  JAMA, 1996
• RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects
  European Journal of Clinical Investigation, 1996
• Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.
  Proceedings of the National Academy of Sciences, 1994
• Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
  Human Molecular Genetics, 1994
• A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
  Nature, 1994
• Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
  Human Molecular Genetics, 1993
• A Comparison of Pentagastrin Injection and Calcium Infusion as Provocative Agents for the Detection of Medullary Carcinoma of the Thyroid¹
  Journal of Clinical Endocrinology & Metabolism, 1974